AstraZeneca (LSE:AZN) has completed its $2bn strategic Investment in Summit Therapeutics, first announced in September 2026, to accelerate development of the bispecific antibody ivonescimab. The investment sits alongside clinical collaborations pairing ivonescimab with AstraZeneca's antibody drug conjugates, including Datroway with Daiichi Sankyo.

What was announced

On 5 October 2026, AstraZeneca PLC announced the completion of its $2bn strategic investment in Summit Therapeutics. The investment, first announced in September 2026, is intended to accelerate the development of ivonescimab, which AstraZeneca describes as "a first-in-class bispecific antibody targeting PD-1 and VEGF", in combination with antibody drug conjugates (ADCs) across tumour types.

The completion announcement is short. It does not state the number of shares acquired, the price paid or the size of AstraZeneca's resulting stake, and it contains no quotes from named executives. It also does not set out any financial impact on AstraZeneca's guidance. The notes to the announcement describe AstraZeneca as headquartered in Cambridge, UK, with medicines sold in more than 125 countries.

The collaborations

Alongside the investment, the companies have entered a clinical collaboration agreement to evaluate sonesitatug vedotin (Sone-Ve) in combination with ivonescimab. AstraZeneca said it also intends to enter an additional agreement for a global development programme combining further AstraZeneca cancer medicines, including additional ADCs, with ivonescimab. That further agreement is described as intended rather than signed.

Separately, AstraZeneca and Daiichi Sankyo have entered a clinical collaboration with Summit to evaluate Datroway (datopotamab deruxtecan) with ivonescimab across multiple tumour types, including lung and breast cancers.

Terms disclosed in September

Further detail on the terms is available from the original announcements, dated 28 September 2026. AstraZeneca's press release said the investment would be made in newly issued preferred stock, comprising approximately 109,000 Preferred Shares convertible into common stock at a ratio of 1:1,000. It put the resulting holding at about 12.0% of Summit's outstanding common stock, or about 10.6% on a fully diluted basis. Summit's own release gave the figure as approximately 108,955 preferred shares and set the price at $18.36 per common stock equivalent, which it said was the Volume weighted-average price for the five prior trading days plus 10%. At that time, closing was expected within about a week, subject to customary conditions.

According to the September releases, Sone-Ve is a Claudin-18.2-targeting ADC being developed for gastrointestinal cancers, licensed from KYM Biosciences in March 2023; AstraZeneca said its CLARITY-Gastric01 trial showed a statistically significant overall survival improvement versus investigator's choice. AstraZeneca also said ivonescimab is in Phase III trials across several indications, including non-small cell and small cell lung cancer, triple-negative breast cancer and colorectal cancer. Summit holds rights to ivonescimab in its licensed territories, which it lists as North America, South America, Europe, the Middle East, Africa and Japan, under a licence from Akeso, which retains rights in China and other regions. Summit said ivonescimab is approved in China but not in its licensed territories, and that a Biologics License Application was submitted to the US Food and Drug Administration in January 2026, with a PDUFA target date of 14 November 2026.

Susan Galbraith, AstraZeneca's Executive Vice President, Oncology Haematology R&D, said in September: "Bispecifics targeting PD-1 and VEGF are rapidly advancing in development and have the potential to improve on current immunotherapies."

What to watch next

With the investment completed, attention turns to the clinical collaborations. Points to watch include the signing of the planned global development agreement for further AstraZeneca medicines with ivonescimab, the design and start of combination studies with Sone-Ve and Datroway, and the US regulatory decision on ivonescimab expected around the November PDUFA date. AstraZeneca has not given a timetable for the collaboration programmes or disclosed any related financial terms beyond the investment.